By The TENS Magazine Editorial Staff
The Advanced Research Projects Agency for Health (ARPA-H), an agency operating within the U.S. Department of Health and Human Services (HHS), has officially announced a commitment of up to $144 million to fund advanced research into human aging and longevity. The funding will be distributed over five years through a newly established initiative called the PROactive Solutions for Prolonging Resilience (PROSPR) program. This represents the largest single federal investment specifically targeted at extending human healthspan—defined as the number of years an individual lives in good health, free from chronic disease and age-related decline.
Historically, the medical community and federal regulators have treated aging as an inevitable backdrop to disease rather than a tractable biological process that can be targeted directly. Consequently, physicians have primarily managed the downstream consequences of aging, such as cardiovascular decline, cognitive loss, frailty, and metabolic dysfunction. Furthermore, clinical trials for longevity interventions have faced significant structural hurdles. Because human aging is a slow process, conventional clinical trials designed to measure lifespan extension or the delay of age-related diseases would take decades to complete, making them unwieldy and prohibitively expensive.
The PROSPR program was designed specifically to overcome these limitations. By funding seven distinct research teams across the United States, ARPA-H aims to identify early, actionable biomarkers of aging. These biomarkers are intended to serve as surrogate endpoints in clinical trials, allowing researchers to measure whether a medical intervention is successfully shifting an individual’s health trajectory within a much shorter timeframe of one to three years.
According to Dr. Alicia Jackson, Director of ARPA-H, the initiative is designed to move the medical system toward evidence-based prevention. “Defeating chronic, debilitating diseases will not just take new therapies, but novel and evidence-based prevention approaches,” Jackson said in a press release. She noted that PROSPR represents a “tectonic shift” in how healthy aging is studied, adding that the agency will push the envelope on new biomarkers, interventions, and clinical trial designs to bring therapies to the public that help Americans stay healthier for longer.
Dr. Andrew Brack, the ARPA-H PROSPR Program Manager, stated that the selected research teams will define the earliest physiological and biochemical changes that predict long-term health outcomes. These discoveries will then be used to fast-track clinically validated therapies aimed at dramatically extending healthspan for millions of aging individuals.
The $144 million investment is distributed among seven academic and biotechnology research teams pursuing diverse approaches to longevity.
The centerpiece of the PROSPR portfolio is the VITAL-H trial (Validation and Intervention Testing for Aging, Longevity and Healthspan). Led by the Barshop Institute for Longevity and Aging Studies at UT Health San Antonio, this project received up to $38 million, the largest single award in the program. The phase 3 hybrid trial will enroll 726 healthy older adults in their 60s to test the efficacy of three Food and Drug Administration (FDA)-approved drugs—an SGLT2 inhibitor, rapamycin, and semaglutide—repurposed specifically for aging-related outcomes.
In the biotechnology sector, Cambrian BioPharma (also known as Cambrian Bio) was awarded up to $30.8 million to support human clinical trials of a daily, oral, next-generation rapamycin analog. This drug is designed to selectively inhibit mTORC1, a signaling pathway whose dysregulation is considered a key driver of age-related metabolic decline. James Peyer, CEO of Cambrian BioPharma, stated that the company’s goal is to treat debilitating conditions at the molecular level before they cause overt disease, focusing on improving “intrinsic capacity,” a composite measure of physical and metabolic resilience.
Another major recipient, Linnaeus Therapeutics, was awarded up to $22 million to explore the age-related benefits of LNS8801, an oncology-derived drug. According to Dr. Patrick Mooney, CEO of Linnaeus Therapeutics, the ARPA-H award validates the potential of LNS8801 to prevent diseases of aging and will enable a rigorous program to translate that promise into clinically meaningful improvements in healthspan-predictive outcomes.
Other funded initiatives under the PROSPR umbrella include a Stanford University-led project to create a validated biological healthspan score, and a first-in-humans study of censavudine, a repurposed HIV medication being tested for its ability to silence retrotransposons, often referred to as “junk DNA,” which are implicated in cellular aging.
The overarching goal of the PROSPR program is to catalyze the creation of a new “healthspan industry”. By establishing a standardized clinical infrastructure and regulatory pathway for longevity therapeutics, ARPA-H hopes to make future healthspan trials faster to design, easier to fund, and more credible to regulatory bodies and clinicians.
Established in 2022 and modeled after the Defense Advanced Research Projects Agency (DARPA), ARPA-H is mandated to fund high-risk, high-reward medical research that falls outside the scope of traditional National Institutes of Health (NIH) grants. The commitment to the PROSPR program signals a historic turning point in federal health policy, shifting the focus from prolonged treatments for late-stage diseases toward proactive solutions that preserve independence and resilience in an aging population.
